Popular Cancer-Related Social Media Posts Can Contain Misinformation
One-third of posts contain misinformation, of which most may be harmful
Prostate And Other Male Cancers
Race May Influence Treatment Receipt in Prostate Cancer
In high treatment benefit category, Black men less likely to receive definitive treatment than non-Black men
Camcevi Approved for Advanced Prostate Cancer
The approval was based on data from a phase 3 study that evaluated the efficacy and safety of Camcevi in 137 adults with advanced prostate cancer.
Pylarify, a PSMA-Targeted PET Imaging Agent, Approved for Prostate Cancer Detection
The approval was based on data from the phase 2/3 OSPREY and phase 3 CONDOR trials that evaluated the diagnostic performance and safety of Pylarify injection.
Nonmetastatic CRPC Treatments Compared for Efficacy and Safety
Investigators compared the efficacy, safety, and costs of abiraterone, darolutamide, enzalutamide, and apalutamide in treating nmCRPC.
Changes in Cancer Incidence, Deaths Expected by 2040
Most common cancers will be breast, melanoma, and lung, while most common cause of cancer-related death will remain lung
Enzalutamide for mHSPC Improves Outcomes, Especially in Black Men
Black men with metastatic hormone-sensitive prostate cancer may have better outcomes if they receive enzalutamide rather than bicalutamide in combination with androgen deprivation therapy, data from a phase 2 trial suggests.
Potential Med Errors Prompt FDA Action on Vinca Alkaloid Labeling
Chemotherapy agents such as vincristine sulfate injection, vinblastine sulfate injection, and vinorelbine tartrate injection should only be prepared in IV infusion bags.
Overall Survival Data Added to Nubeqa Prescribing Information
Nubeqa, an androgen receptor inhibitor, was approved for the treatment of patients with nmCRPC based on data from the placebo-controlled phase 3 ARAMIS trial.
Orgovyx Now Available for Advanced Prostate Cancer
Orgovyx is an oral nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist.
